CA2272644A1 - Composes 2-imidazolinylamino-indazole utiles en tant qu'agonistes de l'adrenorecepteur alpha-2 - Google Patents

Composes 2-imidazolinylamino-indazole utiles en tant qu'agonistes de l'adrenorecepteur alpha-2 Download PDF

Info

Publication number
CA2272644A1
CA2272644A1 CA002272644A CA2272644A CA2272644A1 CA 2272644 A1 CA2272644 A1 CA 2272644A1 CA 002272644 A CA002272644 A CA 002272644A CA 2272644 A CA2272644 A CA 2272644A CA 2272644 A1 CA2272644 A1 CA 2272644A1
Authority
CA
Canada
Prior art keywords
compounds
dosage range
hydrogen
alpha
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002272644A
Other languages
English (en)
Inventor
William Lee Seibel
Sophie Eva Bogdan
Russell James Sheldon
Thomas Lee Cupps
Jeffrey Joseph Ares
Raymond Todd Henry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2272644A1 publication Critical patent/CA2272644A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)

Abstract

L'invention concerne des composés correspondant à la formule (I) dans laquelle: a) R¿1? représente hydrogène ou alkyle, b) R¿2? représente hydrogène, alkyle ou zéro, c) R¿3? représente hydrogène, alcanyle C¿1?-C¿3? non substitué, amino, hydroxy, mercapto, alkylthio C¿1?-C¿3? ou alcoxy, alkylamino C¿1?-C¿3? ou dialkylamino C¿1?-C¿3?, cyano ou halo, d) R¿4?, R¿5? et R¿7? représentent chacun indépendamment hydrogène, alcanyle C¿1?-C¿3? non substitué, alcényle ou alcynyle, cycloalcanyle, cycloalcényle, alkylthio C¿1?-C¿3? non substitué ou alcoxy, hydroxy, thio, nitro, cyano, amino, alkylamino C¿1?-C¿3? ou dialkylamino C¿1?-C¿3? ou halo, e) lorsque R¿2? vaut zéro, la liaison (a) est une liaison double, et f) le composé n'est pas 7-bromo-6-(2-imidazolinylamino)indazole. L'invention concerne également des énantiomères, isomères optiques, stéréo-isomères, diastéréomères, tautomères, sels d'addition, amides et esters biohydrolysables de ces composés, ainsi que des compositions pharmaceutiques contenant de tels composés nouveaux. Elle concerne encore l'utilisation de tels composés dans le traitement ou la prévention de troubles induits par les adrénorécepteurs alpha-2.
CA002272644A 1996-11-25 1997-11-21 Composes 2-imidazolinylamino-indazole utiles en tant qu'agonistes de l'adrenorecepteur alpha-2 Abandoned CA2272644A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3174096P 1996-11-25 1996-11-25
US60/031,740 1996-11-25
PCT/US1997/020551 WO1998023609A1 (fr) 1996-11-25 1997-11-21 Composes 2-imidazolinylamino-indazole utiles en tant qu'agonistes de l'adrenorecepteur alpha-2

Publications (1)

Publication Number Publication Date
CA2272644A1 true CA2272644A1 (fr) 1998-06-04

Family

ID=21861136

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002272644A Abandoned CA2272644A1 (fr) 1996-11-25 1997-11-21 Composes 2-imidazolinylamino-indazole utiles en tant qu'agonistes de l'adrenorecepteur alpha-2

Country Status (20)

Country Link
EP (1) EP0944620A1 (fr)
JP (1) JP2001506599A (fr)
KR (1) KR20000069104A (fr)
CN (1) CN1244864A (fr)
AR (1) AR010643A1 (fr)
AU (1) AU5433998A (fr)
BR (1) BR9713535A (fr)
CA (1) CA2272644A1 (fr)
CO (1) CO4910166A1 (fr)
CZ (1) CZ183999A3 (fr)
HU (1) HUP9904660A3 (fr)
ID (1) ID22676A (fr)
IL (1) IL130067A0 (fr)
NO (1) NO992502L (fr)
NZ (1) NZ335882A (fr)
PE (1) PE47099A1 (fr)
SK (1) SK69699A3 (fr)
TR (1) TR199901542T2 (fr)
WO (1) WO1998023609A1 (fr)
ZA (1) ZA9710576B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908175D0 (en) * 1999-04-09 1999-06-02 Lilly Co Eli Method of treating neurological disorders
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
WO2009084695A1 (fr) 2007-12-28 2009-07-09 Carna Biosciences Inc. Dérivé de 2-aminoquinazoline
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
CN112538074A (zh) * 2020-12-24 2021-03-23 艾希尔（深圳）药物研发有限公司 一种溴莫尼定脱溴杂质的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH641782A5 (en) * 1978-12-07 1984-03-15 Siegfried Ag 1H- and 2H-indazole derivatives
US4526898A (en) * 1980-09-05 1985-07-02 Siegfried Aktiengesselschaft Antihypertensive 4-(2-imidazolin-2-yl-amino)-2-methyl-indazole
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
DK0735877T3 (da) * 1993-12-17 2000-11-06 Procter & Gamble 6-(2-imidazolinylamino)quinoxalinforbindelser, der er egnede som alfa-2-adrenoceptoragonister.

Also Published As

Publication number Publication date
EP0944620A1 (fr) 1999-09-29
KR20000069104A (ko) 2000-11-25
CN1244864A (zh) 2000-02-16
PE47099A1 (es) 1999-06-12
NZ335882A (en) 2000-12-22
HUP9904660A3 (en) 2002-02-28
NO992502D0 (no) 1999-05-25
ID22676A (id) 1999-12-09
SK69699A3 (en) 2000-06-12
NO992502L (no) 1999-07-26
IL130067A0 (en) 2000-02-29
BR9713535A (pt) 2000-03-21
CZ183999A3 (cs) 1999-11-17
AU5433998A (en) 1998-06-22
CO4910166A1 (es) 2000-04-24
TR199901542T2 (xx) 2000-01-21
AR010643A1 (es) 2000-06-28
JP2001506599A (ja) 2001-05-22
ZA9710576B (en) 1998-09-16
HUP9904660A2 (hu) 2000-06-28
WO1998023609A1 (fr) 1998-06-04

Similar Documents

Publication Publication Date Title
CA2271841C (fr) Composes de 2-imidazolinylaminoindole servant de recepteurs adrenergiques alpha-2
AU730369B2 (en) Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6117871A (en) 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US5916900A (en) 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5804587A (en) 6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor agonists
AU736992B2 (en) 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
US5914342A (en) 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
EP0944601B1 (fr) Composes heterocycliques guanidinylamino utiles en tant qu'agonistes de l'adrenorecepteur alpha-2
US6436978B1 (en) Guanidinylamino heterocycle compounds useful as α-2 adrenoceptor agonists
US6172095B1 (en) Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
CA2272644A1 (fr) Composes 2-imidazolinylamino-indazole utiles en tant qu'agonistes de l'adrenorecepteur alpha-2
CA2285610A1 (fr) Composes de 5-(2-imidazolinylamino)benzimidazole utiles en tant qu'agonistes de l'adrenorecepteur alpha-2
WO1998023612A1 (fr) Composes 2-imidazolinylaminobenzothiazole utiles en tant qu'agonistes de l'adrenorecepteur alpha-2

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued